Kotak maintains Reduce rating on Dr. Reddy’s stock on margin miss

Dr. Reddy’s Q4 FY2026 EBITDA missed Kotak’s estimate by 29% after a $50 million Revlimid settlement adjustment and other one-time items, with adjusted EBITDA margin falling to 15.2%. Kotak reiterated a Reduce rating and INR1,175 target, citing limited ANDA approvals and execution risks around Semaglutide ramp-up in Canada and Abatacept launch in the U.S. Management guided for double-digit sales growth excluding generic Revlimid in FY2027, but investors are still digesting the revenue miss of $849 million versus $893 million expected.

Analysis

The key issue is not the one-quarter miss itself; it is that the company is entering a post-exclusivity reset without enough near-term pipeline density to smooth the cliff. When a legacy profit pool rolls off and the next two growth legs are both execution-dependent, the stock typically de-rates on lower visibility rather than absolute earnings power. That is especially true here because the market will treat every quarterly data point as evidence on whether the base business can still fund R&D and defend margins while new launches ramp.

The second-order dynamic is that generic-drug competition is no longer the main debate; launch timing and competitive intensity are. If the Canada semaglutide opportunity ramps slower than expected, or if U.S. abatacept commercialization slips, consensus 12-month EPS likely still proves too high even if top-line growth stabilizes. In that scenario, the shares can remain pinned near lows for months because the investor base will wait for proof of sustained operating leverage rather than pay for optionality.

There is also a relative-value angle: capital is likely to rotate toward more visible global pharma with cleaner growth, while smaller-cap Indian pharma names tied to one or two launch events face multiple compression. The contrarian case is that sentiment may already be close to exhausted; if management delivers even modest sequential margin stabilization and no further launch delays, the stock could squeeze on positioning rather than fundamentals. But that would likely be a tradeable bounce, not a durable rerating, unless the company shows a credible replacement for the lost revlimid economics.

For NVDA, the China-visit headline is mildly supportive only at the margin. The real takeaway is that policy access remains the gating factor, so any incremental upside is likely to come from sentiment and supply-chain optimism rather than a meaningful revision to earnings power; that makes the move more tactical than structural.

Key Decisions for Investors

• Maintain/enter short RDY on strength over the next 2-6 weeks; use any post-earnings bounce to add, targeting a move back toward prior lows on continued estimate cuts. Risk/reward favors the short as long as launch visibility remains poor.
• Pair trade: long a higher-visibility global pharma/large-cap healthcare basket vs short RDY over 1-3 months. The goal is to express a quality/visibility premium as investors rotate away from event-driven earnings risk.
• Buy downside protection in RDY via 3-6 month puts or put spreads if options liquidity allows; define risk tightly and position for another leg lower if semaglutide or abatacept timelines slip.
• For NVDA, treat the China-related catalyst as a short-dated sentiment trade only; consider small tactical calls/call spreads into the visit, but size modestly because the earnings impact is constrained by policy risk.